Nevada Board of Pharmacy agenda posts workshop materials for proposed Schedule I additions: N‑pyrrolidino metonitazene and N‑pyrrolidino protonitazene (NAC 453.510)

The Nevada State Board of Pharmacy posted a first amended agenda (posted Feb 10, 2026) for its March 5, 2026 meeting that includes a workshop item and embedded proposed regulatory text to amend NAC 453.510 (Schedule I) to add the nitazene analogs N‑pyrrolidino metonitazene and N‑pyrrolidino protonitazene. If adopted through the Board’s rulemaking process, these substances would be treated as Schedule I controlled substances in Nevada, triggering associated controlled-substance controls (e.g., prohibitions/limitations on possession and handling, and compliance program updates for registrants).